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Abstract 
Febrile  episodes  and  infections  represent
important complications during antineoplastic
chemotherapy  for  pediatric  neoplastic  dis-
eases.  In  the  last  years  many  international
association published guidelines for the man-
agement of these complications in adults, but
no document of this type was prepared for chil-
dren. One of the major causes of this situation
is probably the very low number of pediatric
clinical trials with adequate power and design.
The paper summarizes guidelines provided for
the management of infectious complications
in adults with cancer by different internation-
al and will comment on how much they may be
translated  in  the  management  of  pediatric
patients. 
Introduction
Febrile  episodes  and  infections  represent
important complications during antineoplastic
chemotherapy  for  pediatric  neoplastic  dis-
eases.  In  the  last  years  many  international
association published guidelines for the man-
agement of these complications in adults, but
no document of this type was prepared for chil-
dren. One of the major causes of this situation
is probably the very low number of pediatric
clinical trials with adequate power and design:
for  example  there  is  only  one  double  blind
placebo-controlled trial of antibacterial prophy-
laxis of febrile neutropenia, published in 2003
and  including  173  patients,1 while  the  first
study on empirical antifungal therapy for per-
sistent  febrile  neutropenia  in  children  was
published in 2010, and included 163 subjects.2
As a consequence, pediatric hematologist and
oncologist frequently apply guidelines imple-
mented for adults even if children present dif-
ferences  as  regards  pharmacology  of  drugs,
epidemiology and, sometimes, clinical features
of  infectious  complications  during  antineo-
plastic chemotherapy. 
In the following paragraphs we will summa-
rize guidelines provided for the management
of infectious complications in adults with can-
cer by different international Societies, i.e. the
European  Conference  for  Infections  in
Leukaemia  (ECIL)  (available  at  http://www.
ichs.org),  Infectious  Diseases  Society  of
America  (IDSA),3)  British  Committee  for
Standards in Haematology (BCSH),4 German
Society  for    Hematology  and  Oncology
(DGHO),5-7 National  Comprehensive  Cancer
Network  (NCCN,  available  at  http://www.
nccn.org),  and  will  comment  on  how  much
they may be translated in the management of
pediatric patients, mainly using as a base an
epidemiological and clinical “common sense”,
more than the availability of adequate pedi-
atric studies. It must be noted that only the
NCCN guideline includes patients with solid
tumors  while  all  the  others  are  referred  to
patients  with  acute  leukemia,  lymphoma  or
myelodisplastic syndrome.
Prophylaxis
In any type of clinical condition the decision
of  administering  anti-infective  prophylaxis
must generally be based on the answers to 4
major questions: i) could you easily treat the
event you are trying to prevent if it happened?
(No: prophylaxis, Yes: no prophylaxis); ii) is it
a severe event? (Yes: prophylaxis, No: no pro-
phylaxis);  iii)  does  the  prophylaxis  have
adverse  effects,  including  development  of
resistance? (No: prophylaxis, Yes: no prophy-
laxis);  iv)  is  the  prophylaxis  effective,  i.e.
which  is  the  number  of  patients  needed  to
treat (NNT) to prevent one event? (low: pro-
phylaxis, high: no prophylaxis).8 The NNT is
calculated with the formula 1/absolute reduc-
tion of the risk (i.e. ratio in the experimental
group – ratio in controls), but there is no stan-
dardization to decide if the NNT is satisfactory,
since it could depend on frequency of the dis-
ease in the controls, consequences of the treat-
ments (efficacy vs. toxicity and/or drug inter-
actions), costs (of prophylaxis and the treat-
ment of the disease if not prevented), selection
of resistances.9
Table 1 summarizes the recommendations
reported in different guidelines for antibacter-
ial and antifungal prophylaxis in adults receiv-
ing antineoplastic chemotherapy. 
As regards the pediatric population the effi-
cacy of antibacterial prophylaxis for the pre-
vention of febrile neutropenia was evaluated
in only one randomized, double blind, placebo-
controlled trial,1 which showed a statistically
significant protective effect in children with
acute leukemia/lymphoma (-17%), but not in
solid  tumors,  with  a  NNT  of  6  patients.
Analyses of studies performed in adults receiv-
ing  fluoroquinolones  showed  a  NNT  of  5
patients to prevent a febrile episode, of 33 to
prevent  one  death  and  of  23  to  prevent  an
infection-related death.10,11 The use of antibac-
terial  prophylaxis  (with  fluoroquinolones,
since we are dealing with adults) is highly rec-
ommended in the ECIL and NCCN guidelines,
but not in the others (Table 1). However, it
must be stressed that no study evaluated the
effects  of  repeated  cycles  of  prophylaxis
administered during the whole course of anti-
neoplastic chemotherapy, and that the wide-
spread use of antibacterial prophylaxis induce
the development of resistance, circumstance
that is becoming one of the major concerns in
supportive care in cancer. 
As regards antifungal prophylaxis, no satis-
factory study evaluated the efficacy and effec-
tiveness  of  this  procedure  in  children.  In
adults,  two  recent  studies  demonstrated  the
higher efficacy of oral posaconazole (-6% of
events)12 or nebulized liposomal amphotericin
B + fluconazole (-10% of events)13 compared
with  other  drugs  or  placebo  in  reducing
proven/probable invasive fungal diseases dur-
ing  repeated  periods  at  risk  following
chemotherapy  for  acute  leukemia.  Posaco  -
nazole prophylaxis is therefore highly recom-
mended by ECIL, DGHO and NCCN, while neb-
ulized liposomal amphotericin B + fluconazole
has a lower level of recommendation in the
ECIL  and  DGHO  guidelines  (Table  1).
Stemming from these proposal, if the reduc-
tion  of  invasive  fungal  disease  observed  in
adults was applied to the epidemiological data
on invasive fungal diseases observed in pedi-
atrics,14-16 the  NNT  in  children  would  range
between 13 and more than 25, with higher val-
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ues in acute lymphoblastic leukemia. However,
some considerations must be done about these
two studies. At present the pediatric dosage of
posaconazole in almost unknown, since it was
evaluated only in 12 children aged 8-17 years,17
and many concern have been raised on phar-
macokinetics parameters of posaconazole that
could  be  of  great  importance  in  pediatrics
(need of a fat meal, or at least supplemental
food  or  acid  drink,  possible  need  of  more
refracted  doses,  avoidance  of  proton-pump
inhibitors or administration through a naso-
gastic tube).18,19 As regards the study with lipo-
somal amphotericin B prophylaxis it must be
noted that it required a very long time (more
than 5 years) to be completed, and this might
have  introduced  a  bias  in  the  evaluation  of
efficacy. Moreover, the compliance with nebu-
lization systems may be lower in younger chil-
dren than in adults. 
Finally, patients with a history of invasive
fungal disease may be at high risk of reactiva-
tion when undergoing further chemotherapy.
In these patients secondary antifungal prophy-
laxis is recommended. The role of secondary
prophylaxis in preventing relapses has never
been studied systematically, even if a longer
duration of antifungal therapy before hemo-
poietic stem cell transplant has been associat-
ed with a better outcome, and the recurrence
of invasive aspergillosis has been attributed to
less than a month of antifungal therapy before
transplant and with persistence of radiological
abnormalities  after  treatment.  The  drug  for
secondary  prophylaxis  should  be  chosen
according to the etiology of the infection, the
localization, the drugs available and their for-
mulations and risks of interactions with other
therapies, especially those for the treatment of
the underlying disease (ECIL). 
Therapy
Fever during neutropenia has always been
considered a medical emergency and should
always  be  considered  as  due  to  infection,
unless otherwise proven. The use of empirical
antibacterial  therapy  in  febrile  neutropenic
cancer patients has been demonstrated to sig-
nificantly improve survival, and it is now con-
sidered one of the cornerstones of the support-
ive care in cancer. In the last years it has been
demonstrated that all cancer patients are not
the same and therefore different anti-bacterial
approaches, oral vs. intravenous, are feasible
in different patients’ groups, e.g. solid tumors
vs.  acute  leukemias.  All  the  guidelines  ana-
lyzed indicate the feasibility of front-line intra-
venous  monotherapy  with  the  use  of  anti-
Pseudomonas  beta-lactams  (ceftazidime,
cefepime or piperacillin-tazobactam or a car-
bapenem) in high-risk patients or the use of
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oral therapy with ciprofloxacin + amoxicillin-
clavulanate in low risk patient’s groups (main-
ly  patients  with  solid  tumors).  As  regards
intravenous  treatment,  the  initial  use  of  an
aminoglycoside should be limited to the combi-
nation  with  ceftriaxone  to  give  coverage
towards Pseudomonas, or in presence of pecu-
liar, local epidemiologic conditions. In case of
empirical administration of an aminoglycoside
its  discontinuation  is  recommended  after  3
days of therapy (3 doses) in patients with fever
of unknown origin. In all guidelines the empir-
ical use of glycopeptides in initial or in pres-
ence of persistent fever is not recommended,
unless  in  presence  of  microbiological  docu-
mentation or clinical signs (e.g. skin and soft
tissue infection and/or signs of central venous
catheter related infection) suggestive of infec-
tion  due  to  methicillin-resistant  Gram-posi-
tives. There are no epidemiological or clinical
reasons to suggest a different approach in the
pediatric population.
The empirical antifungal therapy has been a
common practice in the treatment of persist-
ently febrile neutropenic cancer patients. The
rationale  for  this  practice  was  based  on  old
autopsy  studies,  showing  fungal  infections
undetected during life and on 2 small, random-
ized  studies,  which  enrolled  less  than  200
patients all together. These studies were not
double blind or placebo-controlled and actually
did not conclude an unequivocal advantage for
empirical antifungal therapy. In both studies
the  statistical  power  of  the  observed  results
was very small, especially for subgroup analy-
ses.20 Except the first studies, which used as
main endpoint persistence of fever and sur-
vival, the most recent studies used a very con-
troversial composite clinical endpoint, which
included 5 criteria (defervescence, no discon-
tinuation  for  toxicity,  treatment  of  baseline
fungal infections, prevention of breakthrough
fungal  infections  and  survival).  Many  drugs
have been tested for this indication (liposomal
amphotericin  B,  caspofungin,  voriconazole,
fluconazole),20 but  only  recently  a  pediatric
study was published (liposomal amphotericin
B vs. caspofungin).2 In general, no drug was
significantly  more  effective  than  the  control
one and differences were only based on lower
toxicity. Empirical antifungal therapy after 5
days of persistent febrile neutropenia is still
recommended  by  some  guidelines  (IDSA,
NCCN),  while  in  others  it  is  not  examined
(DGHO),  or  even  discouraged  (BCSH).  The
ECIL guideline recommends this practice with
a low level of evidence, but suggests that it
should be adopted only in centers where rou-
tine CT scan and serum galactomannan anti-
gen detection can not be performed. This rec-
ommendation is acceptable also for the pedi-
atric population. In the last years, awareness
has  grown  that  the  empirical  approach  has
resulted in a tremendous overtreatment of just
a symptom (fever). This realization and recent
advances in diagnosis are making the practice
of  empirical  therapy  more  problematic  and
have  encouraged  development  of  a  different
approach called pre-emptive antifungal thera-
py, aimed at treating a fungal disease when
suggestive but not definitive diagnosis is pres-
ent. The requirement for initiating preemptive
therapy  hinges  around  either  a  radiological
result  (lung  CT  scan)  or  a  microbiological
result (Aspergillus galactomannan in serum or
BAL fluid, glucan detection in serum, cytologi-
cal detection of fungal hyphae or positive cul-
ture on sputum or BAL fluid). At present the
feasibility of the pre-emptive therapy has been
evaluated in 2 studies of management strate-
gy22,23 and in one where pre-emptive therapy
was randomized vs. empirical therapy,21all per-
formed in adults, while no study is available in
pediatrics. These data are not considered suf-
ficient to give a recommendation on the use of
this  approach  to  persistently  febrile  neu-
tropenic patients, neither adults nor children.
Indications for the treatment of documented
infections,  especially  due  to  resistant
pathogens, and/or syndromes due to localized
infections are beyond the scope of the present
document,  but  are  available  in  many  recent
reviews.6,7,20
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